Literature DB >> 3988739

Purification and enzymatic characterization of CMP-sialic acid: beta-galactosyl1----3-N-acetylgalactosaminide alpha 2----3-sialyltransferase from human placenta.

D H Joziasse, M L Bergh, H G ter Hart, P L Koppen, G J Hooghwinkel, D H Van den Eijnden.   

Abstract

A CMP-NeuAc:Gal beta 1----3GalNAc-R alpha 2----3-sialyltransferase has been purified over 20,000-fold from a Triton X-100 extract of human placenta by affinity chromatography on concanavalin A-Sepharose and CDP-hexanolamine-Sepharose in a yield of 10%. Sodium dodecyl sulfate-gel electrophoresis under reducing conditions revealed that the enzyme consists of a major polypeptide species with a molecular weight of 41,000 and some minor forms with molecular weights of 40,000, 43,000, and 65,000, respectively, which can be resolved partially by gel filtration on Sephadex G-100. Isoelectric focusing revealed that the enzyme occurs in a major and a minor charged form with pI values of 5.0-5.5 and 6.0, respectively. Acceptor specificity studies indicated that the enzyme catalyzes the incorporation of sialic acid from CMP-NeuAc into glycoproteins, glycolipids, and oligosaccharides which possess a terminal Gal beta----3GalNAc unit. Analysis of the structure of the product chain by high-pressure liquid chromatography and thin layer chromatography as well as methylation analysis revealed that a NeuAc alpha 2----3Gal beta 1----3GalNAc sequence is elaborated. The best glycoprotein acceptors are antifreeze glycoprotein and porcine submaxillary asialo/afucomucin. The disaccharide Gal beta 1----3GalNAc-Thr shows values for Km and V which are close to those of the latter glycoprotein. Lactose as well as oligosaccharides in which galactose is linked beta 1----3 or beta 1----4 to N-acetylglucosamine are less efficient acceptors. Of the glycolipids tested only gangliosides GM1 and GD1b served as an acceptor. The enzyme does not show an absolute aglycon specificity, and attaches sialic acid regardless the anomeric configuration of the N-acetylgalactosaminyl residue in the accepting Gal beta 1----3GalNAc unit. By use of specific acceptor substrates it could be demonstrated that the purified enzyme is free from other known sialyltransferase activities. Studies with rabbit antibodies raised against a partially purified sialyltransferase preparation indicated that the enzyme is immunologically unrelated to a Gal beta 1----4GlcNAc-R alpha 2----3-sialyltransferase, which previously had been identified in human placenta (Van den Eijnden, D.H., and Schiphorst, W. E. C. M. (1981) J. Biol. Chem. 256, 3159-3162). Initial-rate kinetic studies suggest that the sialyltransferase operates through a mechanism involving a ternary complex of enzyme, sugar donor, and acceptor. This is the first report on the extensive purification and characterization of a sialyltransferase from a human tissue.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3988739

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Reduced sialylation impacts ventricular repolarization by modulating specific K+ channel isoforms distinctly.

Authors:  Andrew R Ednie; Eric S Bennett
Journal:  J Biol Chem       Date:  2014-12-18       Impact factor: 5.157

2.  Purification of alpha 2,6-sialyltransferase from rat liver by dye chromatography.

Authors:  U Sticher; H J Gross; R Brossmer
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857

3.  Benzyl-N-acetyl-alpha-D-galactosaminide inhibits the sialylation and the secretion of mucins by a mucin secreting HT-29 cell subpopulation.

Authors:  P Delannoy; I Kim; N Emery; C De Bolos; A Verbert; P Degand; G Huet
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

4.  UDP-galactose:lactosylceramide alpha-galactosyltransferase activity in human placenta.

Authors:  A Lampio; A Airaksinen; H Maaheimo
Journal:  Glycoconj J       Date:  1993-04       Impact factor: 2.916

5.  Sialyltransferase activity in FR3T3 cells transformed with ras oncogene: decreased CMP-Neu5Ac:Gal beta 1-3GalNAc alpha-2,3-sialyltransferase.

Authors:  P Delannoy; H Pelczar; V Vandamme; A Verbert
Journal:  Glycoconj J       Date:  1993-02       Impact factor: 2.916

6.  Processing O-glycan core 1, Gal beta 1-3GalNAc alpha-R. Specificities of core 2, UDP-GlcNAc: Gal beta 1-3 GalNAc-R(GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase and CMP-sialic acid: Gal beta 1-3GalNAc-R alpha 3-sialyltransferase.

Authors:  W Kuhns; V Rutz; H Paulsen; K L Matta; M A Baker; M Barner; M Granovsky; I Brockhausen
Journal:  Glycoconj J       Date:  1993-10       Impact factor: 2.916

7.  Enzymatic characterization of CMP-NeuAc:Gal beta 1-4GlcNAc-R alpha(2-3)-sialyltransferase from human placenta.

Authors:  M Nemansky; D H van den Eijnden
Journal:  Glycoconj J       Date:  1993-02       Impact factor: 2.916

8.  Sialylation of lacto-N-neotetraosyl ceramide by a solubilized sialyltransferase(s) from chicken skeletal muscle: effect of phosphatidylcholine and sphingomyelin.

Authors:  S Dasgupta; J L Chien; E L Hogan
Journal:  Lipids       Date:  1989-06       Impact factor: 1.880

9.  Expression of N-Acetylglucosaminyltransferase III Suppresses α2,3-Sialylation, and Its Distinctive Functions in Cell Migration Are Attributed to α2,6-Sialylation Levels.

Authors:  Jishun Lu; Tomoya Isaji; Sanghun Im; Tomohiko Fukuda; Akihiko Kameyama; Jianguo Gu
Journal:  J Biol Chem       Date:  2016-01-22       Impact factor: 5.157

10.  Purification and characterization of alpha (2-6)-sialyltransferase from human liver.

Authors:  U Sticher; H J Gross; R Brossmer
Journal:  Glycoconj J       Date:  1991-02       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.